Quipt Home Medical (QIPT) - 2025 Q1 - Quarterly Report

Financial Performance - Total revenue for the three months ended December 31, 2024, was $61,381,000, a decrease of 1.9$62,573,000 for the same period in 2023[17] - Net loss for the three months ended December 31, 2024, was $1,084,000, compared to a net loss of$1,488,000 for the same period in 2023, representing a 27.2% improvement[17] - Operating income for the three months ended December 31, 2024, was $448,000, down from$1,075,000 in the same period of 2023[17] - Total operating expenses for the three months ended December 31, 2024, were $30,398,000, an increase from$29,807,000 in the same period of 2023, reflecting a year-over-year increase of approximately 2%[62] - Adjusted EBITDA for the three months ended December 31, 2024, was $14.0 million, down from$15.3 million in the same period of 2023, reflecting a decrease of 8.6%[74] - The provision for income taxes was $30,000 for the three months ended December 31, 2024, compared to$220,000 for the same period in 2023, indicating a significant reduction of approximately 86%[63] Cash Flow and Liquidity - Cash and cash equivalents at the end of the period were $15,451,000, a decrease from$18,326,000 at the end of the same period in 2023[22] - The company experienced a net cash flow provided by operating activities of $9,300,000 for the three months ended December 31, 2024, compared to$10,606,000 for the same period in 2023[22] - Net cash flow used in investing activities increased to $3,648,000 for the three months ended December 31, 2024, up by 123.4$1,633,000 for the same period in 2023[101] - Net cash flow used in financing activities decreased to $5,522,000 for the three months ended December 31, 2024, down by 32.3$8,158,000 for the same period in 2023[102] Assets and Liabilities - Total assets as of December 31, 2024, were $242,816,000, compared to$247,248,000 as of September 30, 2024[16] - Total liabilities as of December 31, 2024, were $136,502,000, an increase from$140,057,000 as of September 30, 2024[16] - Shareholders' equity decreased to $106,314,000 as of December 31, 2024, from$107,191,000 as of September 30, 2024[16] - The total accounts payable and accrued liabilities decreased to $31,959,000 as of December 31, 2024, from$35,363,000 as of September 30, 2024, indicating a reduction of approximately 9.5%[36] Operational Metrics - The number of patients serviced increased to 157,000, up from 155,000, representing a growth of 1.3% year-over-year[74] - The cost of inventory sold was $17.8 million, representing 28.6$2,800,000 due to changes in accounting treatment, with no change to net loss[69] Legal and Regulatory Matters - The company is facing a civil investigative demand from the DOJ regarding potential false claims related to CPAP equipment, and is cooperating with the investigation[60] - The company has received a subpoena from the SEC related to the DOJ investigation, but the SEC concluded its investigation without recommending enforcement action against the company[61] Shareholder Matters - On January 25, 2025, the company received a notice from Philotimo Fund, LP regarding a proxy contest for four director candidates at the 2025 Annual General Meeting scheduled for March 17, 2025[125] - The company entered into a Non-Disclosure and Standstill Agreement with Forager Fund, L.P. on February 1, 2025, which includes a six-month standstill period preventing Forager from acquiring any equity securities or assets of the company without prior Board approval[126] - The company emphasizes that actions by activist shareholders may negatively impact its strategic plans and long-term value realization[134] - The company faces risks from proxy contests, which could disrupt operations and divert management's attention, potentially leading to loss of business opportunities and difficulties in attracting qualified personnel[134]